Skip to content

Barrx 32041-18-01Recalls & reported problems

Covidien LP · 360 RFA Balloon Catheter · Class 2

All models of Barrx (19)

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 10884521189300), received between Aug 23, 2018 and Aug 23, 2018 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Chest Pain1
  • Pain1
  • Stenosis1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryAug 23, 2018Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    ADULTS WITH DIAGNOSIS OF HIGH-GRADE DYSPLASIA (3) AND MUCOSAL SQUAMOUS CELL CARCINOMAS (7) UNDERWENT CIRCUMFERENTIAL ABLATIONS. FOUR OF THE 7 PATIENTS HAD A HISTORY OF HEAD AND NECK CANCERS, AND 4 HAD A HISTORY OF CIRRHOSIS. ALL PATIENTS HAD LESIONS THAT OCCUPIED MORE THAN HALF OF THE CIRCUMFERENCE OF THE ESOPHAGUS, AND 3 PATIENTS HAD CIRCUMFERENTIAL EXTENSION. PATIENTS UNDERWENT PRIMARY ABLATIONS CIRCUMFERENTIALLY USING THE HALO360 SYSTEM (CONCOMITANT PRODUCTS ENERGY GENERATOR, AND A SIZING BALLOON). ALL PATIENTS UNDERWENT CIRCUMFERENTIAL RFA WITH A DOUBLE-ABLATION REGIMEN (12 J/CM2¿ CLEAN ¿ 12 J/CM2). AFTER ENDOSCOPIC ABLATION, PATIENTS WERE PROVIDED WITH ESOMEPRAZOLE 40 MG/DAY AND SUCRALFATE SUSPENSION 5 ML (200 MG/ML) 4 TIMES DAILY FOR 1 MONTH. ACETAMINOPHEN AND AN ORAL NARCOTIC WERE PRESCRIBED AS NEEDED. PATIENTS LOGGED POSTABLATION SYMPTOMS TO RECORD CHEST PAIN, THROAT PAIN, ODYNOPHAGIA AND DYSPHAGIA. PATIENTS RECEIVED FOLLOW-UP ENDOSCOPY WITH IMAGE ENHANCING MODALITIES, INCLUDING LUGOL STAINING AND NARROW-BAND IMAGING. THIS WAS PERFORMED 1, 3, AND 6 MONTHS AFTER THE PROCEDURE AND EVERY 6 MONTHS THEREAFTER. IF RESIDUAL SQUAMOUS INTRAEPITHELIAL NEOPLASMS WERE DETECTED DURING F

    Patient problems: Chest Pain; Pain; Stenosis

    MAUDE report 7810581 ↗

Other Electrosurgical, Cutting & Coagulation & Accessories devices

All Electrosurgical, Cutting & Coagulation & Accessories devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page